According to Chang Zhaohua, CEO of MicroPort Scientific Corporation, they conducted the clinical trial to further test the stent and compare the results with world-leading heart stents.
"The clinical program adopted European medical standards and was operated by European authoritative experts. We hope to win wider recognition from the international medical community," Chang said.
He said this is the first time that clinical data from a China manufactured stent has been published in such a prestigious medical journal.
"The Lancet is very strict about publishing articles, and the review cycle often lasts for months, sometimes even more than a year. It took less than a month for the journal to publish the clinical trial of the stent, and all five peer review experts gave positive feedback," Chang said.
"With its clinical results being validated in such a rigorous peer-reviewed publication, clinicians and patients may have more confidence in the safety and efficacy of the stent," he added.
According to statistics from the National Cardiovascular Center, there were 290 million cardiovascular patients in China in 2017, including 11 million patients with coronary heart disease.
China has a huge demand for medical devices such as heart stents. The market used to be dominated by costly foreign products.
Many Chinese healthcare companies have increased their research and development in high-end medical devices, making them more affordable to the public.
【国内英语资讯:China Focus: Chinas self-developed heart stent wins worldwide recognition】相关文章:
★ 沙特大幅减产石油
★ 风暴之后
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15